Almost a third of people treated with the higher dose had a bodyweight reduction of more than 25%, and 83.4% of patients with prediabetes at the start of the trial had returned to normal blood sugar levels by the end of the trial, compared to 73.8% for the standard dose and 36.6% for the placebo group
Frontiers in Pharmacology, 16, 1438318
Call Prestons Pharmacy Today
Limitations and Future Research While initial findings are encouraging, there are limitations to the current research
Several states have rules like this or require the physician to register with the pharmacy board if they want to dispense medications
Methods Trial design and participants This phase 3, randomized, double-blind, placebo-controlled study was conducted at 41 sites across five countries (Canada, Italy, Hungary, Spain and the United States), as described in a previous publication 8 and listed in the Supplementary information